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In the rat liver epithelial cell lines GN4 and WB, an-
giotensin II (Ang II) activates the Gq class of regulatory
G-proteins, increasing intracellular calcium, protein ki-
nase C activity, and protein tyrosine phosphorylation.
We compared the ability of Ang II and other compounds
that increase intracellular calcium (i.e. the calcium
ionophore A23187 and thapsigargin) or protein kinase C
activity (the phorbol ester 12-O-tetradecanoylphorbol-
13-acetate) to activate p70 ribosomal S6 kinase (p70S6K)
and p90 ribosomal S6 kinase (p90RSK). In GN4 cells, in-
creasing intracellular calcium stimulated p70S6K activ-
ity in a rapamycin- and wortmannin- sensitive manner,
but did not affect p90RSK activity. In contrast, 12-O-tet-
radecanoylphorbol-13-acetate strongly activated p90RSK
but only weakly stimulated p70S6K. The ability of cal-
cium to activate p70S6K was confirmed by blocking the
A23187-dependent activation through chelation of ex-
tracellular calcium with EGTA; the effect of thapsigar-
gin was inhibited by the cell permeant chelator bis-(o-
aminophenoxy)ethane-N,N,N*,N*-tetraacetic acid tetra-
acetoxymethyl ester (BAPTA-AM). Similarly, BAPTA-AM
prevented the activation of p70S6K by Ang II, suggesting
that this signal was largely calcium-dependent. In con-
trast, the Ang II-dependent activation of mitogen-acti-
vated protein kinase and p90RSK was not inhibited but
was enhanced by BAPTA-AM. These results show that in
GN4 cells, Ang II selectively activates p70S6K through
effects on calcium, p90RSK through effects on protein
kinase C. The activation of p70S6K by calcium stimuli or
Ang II was independent of calmodulin but correlated
well with the activation of the recently identified, non-
receptor calcium-dependent tyrosine kinase (CADTK)/
PYK-2. Both calcium- and Ang II-dependent activation
of p70S6K were attenuated by the tyrosine kinase inhib-
itor genistein, and activation of p70S6K was higher in
GN4 than WB cells, correlating with the increased ex-
pression and activation of CADTK/PYK-2 in GN4 cells. In
summary, these results demonstrate that intracellular
calcium selectively activates p70S6K in GN4 cells, con-
sistent with increased CADTK/PYK-2 signaling in these
cells.
The peptide hormone angiotensin II (Ang II)1 initiates mul-
tiple intracellular processes that in some cell types influence
cell proliferation. The seven-transmembrane-spanning Ang II
receptor is coupled to the Gq class of regulatory G-proteins,
which, when activated, stimulates inositol phosphate-mediated
calcium release, protein kinase C activity, and additional sig-
nals regulated by bg subunits (1). In rat liver epithelial cells,
an additional response to Ang II is a rapid (15–60 s), calcium-
dependent increase in tyrosine phosphorylation of proteins (2,
3). One of the tyrosine-phosphorylated proteins has been puri-
fied from Ang II-treated rat liver epithelial cells using ATP
affinity chromatography as the penultimate step and shown to
be the major calcium-dependent protein tyrosine kinase
(CADTK) in these cells (4). Although not directly activated by
calcium in vitro, this kinase is stimulated by treatment of cells
with agonists and hormones that elevate intracellular calcium
(3, 4). Peptide sequencing of the purified kinase and cDNA
cloning using rat liver epithelial cell mRNA revealed a novel
cytoplasmic tyrosine kinase highly related to the p125 focal
adhesion kinase (5). The kinase has also been recently identi-
fied by three other groups. One group using a polymerase chain
reaction strategy to search for novel kinases cloned the human
sequence PYK-2 and have also shown its activation in a calci-
um- and PKC-dependent manner (6). Two other groups screen-
ing for kinases related to p125 focal adhesion kinase have
reported the sequence as cell adhesion kinase b and related
adhesion focal tyrosine kinase (7, 8).
In addition to stimulation of calcium and calmodulin, PKC,
MAPK, c-Jun N-terminal protein kinase (JNK), and CADTK/
PYK-2 (1, 9, 10), Ang II has been shown to activate the riboso-
mal p70 S6 kinase (p70S6K) (11). This ubiquitous class of mi-
togen-activated protein kinases is best known for their ability
to phosphorylate the S6 protein of the 40 S ribosome (reviewed
in Ref. 12). Although related in sequence to another S6 kinase
(p90RSK), the regulation of p70S6K is clearly distinct from the
p90RSK, the latter being activated as part of the Ras-dependent
MAPK cascade (13). In contrast to p90RSK, activation of the
p70S6K pathway is inhibited by rapamycin (14, 15). In mam-
mals, the intracellular target for rapamycin is the binding
protein FKB12, which forms a complex with the recently iden-
tified protein kinases known as FRAP and RAFT (16, 17).
Similar in sequence homology to the phosphatidylinositol-3
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kinases (PI-3 kinases) (18), the FRAP/RAFT kinase is required
for activation of p70S6K (16) but does not appear to phospho-
rylate phosphatidylinositol, PI-3 kinase, or p70S6K. Thus the
mechanism by which FRAP/RAFT regulates p70S6K signaling
remains to be elucidated.
The p70S6K can be activated by numerous stimuli, including
growth factors, inhibitors of protein synthesis (cycloheximide
or anisomycin), and, as noted above, hormones such as Ang II
(11, 19, 20). Complete activation of p70S6K appears to require
multisite phosphorylation by several protein kinases, at least
one of which is proline-directed and phosphorylates a sequenc-
e(s) in the C-terminal region of the S6 kinase (21–24). Despite
the knowledge of specific phosphorylation sites, the activating
“S6 kinase kinases” remain to be identified. In addition to the
involvement of the rapamycin-sensitive FRAP/RAFT men-
tioned above, p70S6K is inhibited by wortmannin and
LY294002, implicating PI-3 kinase in the signaling to p70S6K
(25, 26). These results are further supported by studies involv-
ing expression of a constitutively active PI-3 kinase (27). A
potential intermediary for PI-3 kinase in p70S6K activation is
the serine and threonine kinase PKB, also known as Akt (28,
29), which has been shown to activate p70S6K when co-ex-
pressed in cells (30).
The p70S6K is involved in mitogenesis; studies with neutral-
izing antibodies to p70S6K or the inhibitor rapamycin have
shown that this kinase is required for G1 progression (31–33).
The ability of p70S6K to phosphorylate the ribosomal S6 protein
has been well characterized (34), but the contribution of this
event to the regulation of protein synthesis is less clear (re-
viewed in Ref. 12). Phosphorylation of the S6 protein has been
found to enhance the translation of mRNAs containing 59-poly-
pyrimidine tracts (35, 36), and it is likely that p70S6K plays a
role in growth-related control of translation. For example,
translation of specific messages such as those encoding elonga-
tion factor 1a (36) or insulin-like growth factor II (37) appear to
be regulated by the S6 pathway; these may be members of a
class of proteins required for progression through the G1 phase
of the cell cycle.
Ang II also stimulates protein synthesis in a number of cell
types (11, 38), an event that may be dependent on calcium (39)
and p70S6K (11). Because of our interest in calcium and Ang II
signaling, we compared the ability of these stimuli to activate
the p70S6K in liver epithelial cells, cells known to have a pro-
liferative response to Ang II (1). In addition, Ang II leads to a
protein kinase C-independent increase in AP1 binding, as well
as stimulation of MAP kinase and c-Jun N-terminal kinase (10)
and a calcium-dependent activation of a novel; calcium-depen-
dent tyrosine kinase (CADTK). In this article we describe the
finding that agents and hormones that increase intracellular
calcium activate p70S6K but not p90RSK. Furthermore, these
studies suggest that the initial steps in Ang II action are well
correlated with activation of CADTK.
EXPERIMENTAL PROCEDURES
Materials—Human Ang II (DRVYIHPF) was obtained from Sigma
and prepared in 50 mM acetic acid prior to use. The S6 peptide (RRLSS-
LRA) (40) and PKI peptide (TTYADFIASGRTGRRNAIHD) (41) were
synthesized by Dr. D. Klapper (University of North Carolina, Chapel
Hill, NC). Thapsigargin, A23187, bis-(o-aminophenoxy)ethane-
N,N,N9,N9-tetraacetic acid tetraacetoxymethyl ester (BAPTA-AM), 12-
O-tetradecanoylphorbol-13-acetate (TPA), calyculin A, wortmannin, ra-
pamycin, anisomycin, and calmidizolium were obtained from Biomol
and prepared in Me2SO. Calmodulin, leupeptin, and aprotinin were
obtained from Sigma. Epidermal growth factor (EGF) was obtained and
used as described previously (10). The intact 40 S ribosomal subunit
was purified from rat liver by the procedure of Terao and Ogata (42).
Cell Culturing and Harvesting—Rat liver epithelial cells (GN4 or
WB) were grown at 37 °C in Richter’s minimal essential media contain-
ing 0.1 mM insulin and supplemented with 10% fetal bovine serum in a
humidified 5% CO2 atmosphere as described earlier (3). Cells were
serum starved (0.1% fetal bovine serum) for 20–24 h prior to agonist
stimulation. Cells were washed twice with phosphate-buffered saline
(PBS) and once with Buffer H (50 mM b-glycerophosphate, pH 7.4, 1.5
mM EGTA, 0.15 mM sodium orthovanadate, 1 mM dithiothreitol, 25
mg/ml leupeptin, and 1 mM phenylmethylsulfonyl fluoride), after which
they were scraped in 0.5 ml of Buffer H. The cells were then sonicated
with two 5-s pulses (Fisher MDL 550 Sonic Dismembrator), and the
lysates were centrifuged at 100,000 3 g (4 °C).
p70S6K Assays—The activity of p70S6K in cell lysates was determined
as described earlier (43). The 100,000 3 g supernatants were assayed
for p70S6K activity by monitoring the phosphorylation of the ribosomal
protein S6 (2 mg) in a buffer (30 ml) containing 25 mM b-glycerophos-
phate (pH 7.4), 1.5 mM EGTA, 0.1 mM Na3VO4, 1 mM dithiothreitol, 10
mM MgCl2, 10 mM calmidizolium, 2 mM PKI peptide, and 100 mM
[g-32P]ATP (2000 mCi/mmol) for 20 min at 30 °C. The reactions were
terminated by the addition of SDS-PAGE sample buffer (30 ml), heated,
and applied to SDS-PAGE (10% acrylamide). The radioactive band
corresponding to the ribosomal S6 protein was identified by staining
with Coomassie Blue and autoradiography; the radioactive band was
excised from the dried gel and quantitated by liquid scintillation count-
ing. Calmidizolium (10 mM) was included in the assay mixture to pre-
vent the phosphorylation of the ribosomal S6 protein by calcium- and
calmodulin-dependent kinases.
Immunoprecipitation Assays for p70S6K and p90RSK—In some exper-
iments, p70S6K was assayed by immunoprecipitation of the p70S6K after
lysis of the cells in Tris/Triton lysis buffer (20 mM Tris, pH 7.5, 137 mM
NaCl, 1% Triton X-100, 10% glycerol, 2 mM EDTA, 0.5 mM phenylmeth-
ylsulfonyl fluoride, 5 mg/ml leupeptin, 10 nM calyculin A, and 148 mM
Na3VO4). The samples were immunoprecipitated as described below
and the immunoprecipitate/protein A-agarose beads were washed once
with Tris/Triton lysis buffer and twice with PBS (1 ml). The S6 kinase
assays were performed using a modification of the above assay proce-
dure. In these assays, the immunoprecipitate/protein A-agarose beads
(20 mL) were assayed in 20 mM Hepes, pH 7.3, 10 mM b-glycerophos-
phate, 1.5 mM EGTA, 0.1 mM Na3VO4, 1 mM dithiothreitol, 10 mM
MgCl2, and 50 mM [g-
32P]ATP (1000 mCi/mmol) plus 250 mM S6 peptide
in a final reaction volume of 60 ml. The assay was performed at 30 °C for
20 min with constant shaking in an Eppendorf 5436 Thermomixer. The
reaction was terminated by the addition of 20 ml of 100 mM EDTA (pH
7.0); the samples were centrifuged for 5 min at 13,000 3 g, and the
supernatant (40 ml) was spotted on Whatman P-81 paper. The papers
were washed in 10% phosphoric acid, and the radioactivity incorporated
into S6 peptide was determined by liquid scintillation counting. The
assays for p90RSK were performed exactly as described above, except the
cell lysates were immunoprecipitated with a rabbit polyclonal antibody
developed against the C terminus of p90RSK as described previously
(Ref. 44; kindly provided by Dr. Edwin G. Krebs, Department of Phar-
macology, University of Washington).
p70S6K Immunoprecipitation and Immunoblotting—For immunode-
tection of p70S6K, cells were washed as described above and lysed in
RIPA buffer containing 20 mM Tris (pH 7.4), 137 mM NaCl, 10% glyc-
erol, 0.1% SDS, 0.5% deoxycholate, 1.0% Triton X-100, and 2.0 mM
EDTA plus 10 nM calyculin A and 0.5 mM phenylmethylsulfonyl fluo-
ride. The lysates were centrifuged at 13,000 3 g for 10 min (4 °C). The
samples were immunoprecipitated using a rabbit polyclonal antibody
developed against a C-terminal peptide (QAFPMISKRPEHLRMNL) of
the p70S6K (kindly provided by Dr. J. Weiel, Glaxo-Wellcome). Immu-
noprecipitation was facilitated by the addition of protein A-agarose (20
ml, packed beads), and the immunoprecipitates were washed three
times with RIPA buffer prior to addition of SDS-PAGE sample buffer.
Samples were applied to SDS-PAGE and blotted to polyvinylidene
difluoride, and the immunoprecipitated p70S6K was detected by incu-
bating blots with the C-terminal p70S6K antibody (diluted 1:2500 in
TBST). The immunoblot was incubated with goat anti-rabbit (alkaline
phosphatase-conjugated) antibodies (diluted 1:5000 in TBST), and the
color was developed according to the manufacturer’s procedure
(Promega).
Measurement of CADTK Tyrosine Autophosphorylation—The activ-
ity of CADTK was assayed by determining the amount of tyrosine
autophosphorylation by a modification of the procedure described ear-
lier (4). Briefly, the cells were washed twice with PBS and harvested in
RIPA or Tris/Triton lysis buffer as described above for the S6 kinase
immunoblotting experiments. The CADTK was immunoprecipitated
with a rabbit polyclonal antibody developed against a glutathione S-
transferase-CADTK fusion protein (5). The CADTK immunoprecipi-
tates were washed three times with RIPA or Tris/Triton lysis buffer and
applied to SDS-PAGE (8% acrylamide). After electrophoresis the pro-
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teins were transferred electrophoretically to nitrocellulose, and the
amount of phosphotyrosine on CADTK was quantitated by antiphos-
photyrosine immunoblotting (PT66) and ECL as described earlier (4).
RESULTS
Calcium Activates p70S6K but Not p90RSK—Incubation of
GN4 rat liver epithelial cells with compounds that increase
intracellular calcium (i.e. the ionophore A23187, thapsigargin
(which releases calcium from internal stores; Ref. 45), or Ang
II), stimulates intracellular protein tyrosine phosphorylation
(2). To investigate the influence of calcium-stimulated tyrosine
phosphorylation on “downstream” kinase signaling pathways,
we examined the ability of calcium to activate the ribosomal S6
kinase p70S6K. Incubation of GN4 cells with 1 mM A23187 or 2
mM thapsigargin increased S6 kinase activity as measured by
the phosphorylation of the 40 S ribosomal S6 protein (Fig. 1A).
A typical response to these stimuli was a 2–3-fold increase over
basal levels, similar to that produced by EGF (See Fig. 3). The
calcium-stimulated increase in S6 kinase activity was inhibited
by the calcium chelators EGTA and BAPTA-AM. Preincubation
with EGTA prevented activation of p70S6K by A23187; the
cell-permeant chelator BAPTA-AM (BAPTA) inhibited both the
thapsigargin- and ionophore-stimulated S6 kinase activity
(Fig. 1A). These results indicate that for these agonists the
increase in p70S6K activity is calcium-dependent, and with
thapsigargin, the effect is primarily dependent on intracellular
calcium.
In addition to the increased the phosphorylation of the ribo-
somal S6 protein, calcium activated p70S6K as demonstrated by
SDS-PAGE and immunoblotting analysis (Fig. 1B). In these
experiments, p70S6K was immunoprecipitated from cell lysates
and immunoblotted for p70S6K as described under “Experimen-
tal Procedures.” Four immunoreactive bands corresponding to
the multiple phosphorylated forms of p70S6K were detected
(46). In all experiments, increased p70S6K activity (as deter-
mined by S6 protein phosphorylation) correlated with an up-
ward mobility shift of both the slowest and fastest migrating
immunoreactive bands on SDS-PAGE. The increased upward
mobility shift of p70S6K produced by A23187, or thapsigargin
was prevented by preincubation with calcium chelators (Fig.
1B). BAPTA preincubation reduced the mobility shift of p70S6K
from untreated and A23187- or thapsigargin-treated cells,
demonstrating that BAPTA affected both the stimulated and
basal S6 kinase activity. In contrast, EGTA inhibited only the
A23187-stimulated S6 kinase mobility shift, similar to the re-
sults obtained by assaying S6 protein phosphorylation. (Fig. 1,
A and B).
Like thapsigargin, Ang II rapidly increases intracellular cal-
cium and tyrosine phosphorylation in rat liver epithelial cells
(2). As shown in Fig. 2, incubation of GN4 cells with Ang II
rapidly stimulated p70S6K activity comparable with that ob-
served with thapsigargin. The increase in p70S6K activity was
apparent as early as 2–5 min after Ang II addition, with the
peak of S6 phosphorylation occurring after 10–20 min. The
effect of Ang II and thapsigargin was sustained for more than
60 min (data not shown). Similar results were found by ana-
lyzing immunoblots of p70S6K; Ang II, thapsigargin, and
A23187 stimulated a time-dependent increase in the p70S6K
mobility shift on SDS-PAGE, which paralleled the increase in
S6 protein phosphorylation (see Fig. 4A).
In cardiac myocytes, Ang II and calcium have been reported
to stimulate the activity of MAPK and the ribosomal S6 kinase
p90RSK (47). Although Ang II activated MAPK in GN4 cells by
FIG. 1.Calcium agonists activate p70S6K. A,GN4 cells were grown
in 10-cm dishes and serum-starved as described under “Experimental
Procedures.” The cells were then incubated with 1 mM A23187 or 2 mM
thapsigargin (Thaps) for 10 min. In some experiments, the calcium
chelators EGTA (5 mM) and BAPTA (50 mM) were added to the medium
15 min prior to the addition of calcium stimuli. The cells were harvested
and assayed for S6 kinase activity as described under “Experimental
Procedures,” and the S6 kinase activity is plotted as radioactivity (cpm,
32P) incorporated into the ribosomal S6 protein. The results represent
the mean 6 S.E. (bars) of duplicate samples. Data plotted are repre-
sentative of n 5 2 experiments. B, cells were prepared as described in
A and treated with calcium agonists for the lengths of time indicated at
the bottom. In some experiments cells were incubated with PBS (C), 5
mM EGTA (E), or 50 mM BAPTA (B) for 15 min prior to the addition of
calcium stimuli. The cell lysates were prepared by washing the cells
twice with PBS and adding 1 ml of RIPA buffer to solubilize the cells.
The cell lysate was clarified by centrifugation at 12,000 3 g prior to the
addition of antisera to p70S6K. The immunoprecipitated p70S6K was
identified by SDS-PAGE and immunoblotting as described under “Ex-
perimental Procedures.”
FIG. 2. Angiotensin II and thapsigargin increase p70S6K activ-
ity. GN4 cells were prepared as described in the legend to Fig. 1 and
incubated with 1 mM Ang II (l) or 2 mM thapsigargin (f) for the lengths
of time indicated. The cells were harvested, and the cell lysates were
assayed for S6 kinase activity as described earlier. The S6 kinase
activity is plotted as radioactivity (cpm, 32P) incorporated into the
ribosomal S6 protein, and the results represent the mean 6 S.E. (bars)
of duplicate samples. Data plotted are representative of n 5 3
experiments.
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a PKC-dependent mechanism, thapsigargin does not stimulate
MAPK in these cells (5, 10). We therefore compared the ability
of thapsigargin and EGF to activate p70S6K and p90RSK in GN4
cells. As expected, both agonists stimulated p70S6K (Fig. 3A),
but only EGF stimulated p90RSK in GN4 cells (Fig. 3B). The
kinase assay on p90RSK immunocomplexes using the S6 pep-
tide (RRLSSLRA) as a substrate also demonstrated that
A23187 did not activate p90RSK, whereas Ang II potently acti-
vated this enzyme, as previously reported (10) (data not
shown).
Calcium-dependent p70S6K Activation Is Inhibited by Wort-
mannin and Rapamycin—To further rule out the possibility
that p90RSK was contributing to the phosphorylation of the S6
protein in cell lysates and to investigate the mechanism by
which calcium stimulates p70S6K, we examined the effect of
compounds known to inhibit p70S6K activation. Rapamycin has
been previously shown to inhibit p70S6K without affecting
p90RSK activity (14, 15). As shown in (Fig. 4A), incubation of
cells with 10 nM rapamycin completely inhibited the Ang II-
and calcium ionophore (A23187)-stimulated increase in p70S6K
S6 peptide kinase activity. Similarly, rapamycin blocked the
thapsigargin-dependent activation of p70S6K; (unstimulated,
35.7 6 0.4 pmol/min/ml; thapsigargin, 94.3 6 7.1 pmol/min/ml;
thapsigargin and rapamycin, 23.9 6 0.2 pmol/min/ml). Rapa-
mycin also blocked Ang II-, A23187-, and thapsigargin-depend-
ent p70S6K activation, as assessed by the gel mobility immuno-
blotting (Fig. 4B). These results demonstrate that Ang II and
calcium stimulate p70S6K through a rapamycin-sensitive path-
way and confirm that p70S6K and not p90RSK is the major
ribosomal S6 kinase activated by calcium stimuli in GN4 cells.
Studies with the inhibitor wortmannin and constitutively
active forms of PI-3 kinase have demonstrated a role for this
enzyme in the regulation of p70S6K (25–27). To determine
whether calcium stimulated p70S6K through a PI-3-kinase-de-
pendent pathway, the effect of wortmannin on p70S6K activity
was examined. As shown in Fig. 4B, incubation of GN4 cells
with wortmannin (50 nM) inhibited the mobility shift of p70S6K
stimulated by Ang II, A23187, or thapsigargin. The inhibition
FIG. 3. Thapsigargin activates p70S6K, but not p90RSK. Serum-
starved GN4 cells were incubated with 2 mM thapsigargin (Thaps) or 6.6
nM EGF for the lengths of time indicated. The cells were washed two
times with PBS and harvested in Tris/Triton lysis buffer as described
under “Experimental Procedures.” The lysate from each 10-cm dish was
immunoprecipitated with antibodies specific for p70S6K (A) or p90RSK
(B) and assayed for S6 peptide kinase activity as described above. The
S6 peptide activity is plotted as the amount of activity (pmol/min/ml),
and the results represent the mean 6 S.E. (bars) of duplicate samples.
Data plotted are representative of n 5 3 experiments. cont, control.
FIG. 4. Rapamycin and wortmannin inhibit the activation of
p70S6K by calcium agonists. A, GN4 cells were incubated with 0.1%
Me2SO (carrier for rapamycin) or rapamycin (Rap, 10 nM, 15 min) prior
to the addition of A23187 (1 mM) or Ang II (AgII, 1 mM). Cell lysates were
prepared as described earlier, and the S6 kinase activity is plotted as
radioactivity (cpm, 32P) incorporated into the ribosomal S6 protein. The
results represent the mean 6 S.E. (bars) of duplicate samples. Data
plotted are representative of n 5 3 experiments. B, GN4 cells were
incubated with 1 mM Ang II, 2 mM thapsigargin or 1 mM A23187 for the
lengths of time indicated. In some experiments, cells were incubated
with 10 nM rapamycin (R) or 50 nM wortmannin (W) for 15 min prior to
the addition of agonist. The p70S6K was immunoprecipitated and de-
tected by immunoblotting as described in the legend to Fig. 1.
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of p70S6K by wortmannin occurred at low concentrations
(10–50 nM), consistent with the effects of this compound on PI-3
kinase (48). Similar inhibitory affects of wortmannin were
found on the calcium-dependent activation of S6 kinase, as
determined by S6 protein phosphorylation (data not shown).
Thus, this calcium-stimulated signaling pathway appears to be
mediated through both a PI-3 kinase and FRAP/RAFT-depend-
ent pathway.
Angiotensin II Activates p70S6K in a Calcium-dependent
Manner—Ang II stimulates an inositol phosphate-mediated
increase in intracellular calcium (reviewed in Ref. 49), and
since our results demonstrated that calcium stimulates p70S6K
activity, we examined whether the activation by Ang II was
calcium-dependent. Incubation of GN4 cells with the calcium
chelator BAPTA inhibited the Ang II-stimulated S6 kinase
activity in a dose-dependent manner, with .90% inhibition
occurring at 50 mM BAPTA (Fig. 5A). Like the results found
with S6 kinase activity, BAPTA inhibited the Ang II-stimu-
lated p70S6K mobility shift (Fig. 5B) at concentrations similar
to those required to inhibit the activation by A23187 or thap-
sigargin (Fig. 1, A and B). Chelation of extracellular calcium
with EGTA (5 mM) only minimally affected the Ang II-stimu-
lated S6 kinase activity, further supporting the thesis that
intracellular calcium was required for the activation of p70S6K
(Fig. 5B). The calcium-dependent activation of p70S6K occurred
independently of calmodulin, since the calmodulin inhibitor
calmidizolium (50) did not inhibit this event. Similarly, neither
calmidizolium nor W-7 prevented the autophosphorylation of
CADTK, although calmidizolium (15 mM) inhibited the Ang
II-dependent activation of the myosin light chain peptide ki-
nase activity, a known calmodulin-dependent process (data not
shown). In comparison, preincubation of GN4 cells with
BAPTA did not inhibit but significantly stimulated the activa-
tion of p90RSK by Ang II in a dose-dependent manner (Fig. 5C).
Furthermore, incubation with BAPTA alone (50 mM) increased
the basal level of p90RSK to levels equivalent to that of Ang II
stimulation in these cells. Similar to the results obtained with
p90RSK, BAPTA pretreatment potently enhanced the basal and
Ang II-stimulated level of MAPK activity (data not shown).
PKC Activates p90RSK but Not p70S6K in GN4 Cells—Since
Ang II increases diacylglycerol formation and PKC activity in
GN4 cells, we investigated whether the activation of p70S6K by
Ang II was also PKC-dependent. Incubation of cells with phor-
bol ester (TPA, 100 nM) for 20 min did not stimulate p70S6K
activity in these cells, although p90RSK was stimulated by TPA
(100 nM, 5 min) (Fig. 6, A and B). To further investigate the
involvement of PKC, PKC activity was down-regulated by
chronic incubation with TPA (1 mM, 24 h). The activation of
p70S6K by Ang II was not inhibited by this treatment, indicat-
ing that PKC did not play a substantial role in regulating
p70S6K in these cells (Fig. 6A). In comparison, this treatment
effectively eliminated the activation of p90RSK by TPA as ex-
pected (Fig. 6B).
The Activation of p70S6K by Calcium Requires a Tyrosine
Kinase—In epithelial cells, the Ang II- and calcium-stimulated
increase in protein tyrosine phosphorylation is inhibited by the
tyrosine kinase inhibitor genistein (3, 51). GN4 cells were
briefly incubated with genistein (10–200 mM) to test the ability
of this compound to prevent the activation of p70S6K by Ang II
or calcium stimuli. As shown in Fig. 7A, genistein inhibited the
Ang II-stimulated p70S6K activity in a dose-dependent manner,
suggesting the involvement of a tyrosine kinase in the calcium
and Ang II signaling to p70S6K. Similarly, genistein inhibited
the activation of p70S6K by thapsigargin (data not shown).
Recently, we have purified the major calcium- and Ang II-
stimulated tyrosine kinase (CADTK) from GN4 rat liver epi-
FIG. 5. Angiotensin II activates p70S6K in a calcium-dependent
manner. A, p70S6K activity. Serum-starved GN4 cells were incubated
with 1 mM Ang II for 20 min; in some experiments cells were incubated
with the indicated concentrations of BAPTA for 15 min prior to the
addition of Ang II (AgII). Cell lysates were prepared, and the p70S6K
was immunoprecipitated and assayed as described earlier. The p70S6K
activity is plotted as pmol/min/ml, and the results represent the mean6
S.E. (bars) of duplicate samples. B, serum-starved GN4 cells were
incubated with Me2SO (carrier), 5 mM EGTA (E), or 50 mM BAPTA (B)
for 15 min prior to the addition of Ang II (1 mM) for the amount of time
indicated; p70S6K was analyzed for activity by SDS-PAGE immunoblot-
ting as described earlier. C, p90RSK activity. Cells were treated exactly
as described in A, and the p90RSK was immunoprecipitated and assayed
as described earlier. The p90RSK activity is plotted as pmol/min/ml, and
the results represent the mean 6 S.E. (bars) of duplicate samples. Data
plotted are representative of n 5 3 experiments. Cont, control.
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thelial cells (4), cloned the cDNA, and raised specific antisera to
the protein (5). We compared the ability of genistein to inhibit
the activity of CADTK by assaying the tyrosine autophospho-
rylation of CADTK, as described under “Experimental Proce-
dures.” The amount of tyrosine autophosphorylation of this
kinase appears to be proportional to the enzymatic activity.2 As
shown in Fig. 7B, incubating GN4 cells with concentrations of
genistein from 50 to 400 mM led to a progressive decrease in the
Ang II-stimulated CADTK tyrosine autophosphorylation. Sim-
ilar concentrations of genistein were required to inhibit the
tyrosine autophosphorylation of the EGF receptor in these
cells. In comparison, the calcium-dependent tyrosine phospho-
rylation of an exogenous substrate (e.g. paxillin, a 68–70-kDa
protein) tyrosine-phosphorylated by CADTK was inhibited by
even lower concentrations of genistein (100–200 mM) than was
the CADTK autophosphorylation.3 The results with genistein
implicate a tyrosine kinase in the activation of p70S6K by cal-
cium or Ang II, suggesting a role for CADTK.
The Stimulation of p70S6K Correlates with Increased CADTK
Activity—To further investigate whether CADTK was involved
in the regulation of p70S6K, we compared the activation of
p70S6K in cells known to exhibit different levels of Ang II- and
thapsigargin-dependent CADTK activation. Previously we
showed that transformed GN4 rat liver epithelial cells exhibit
approximately 3–4 times more Ang II-stimulated tyrosine
phosphorylation than the parental cell type from which it was
derived (WB) (3). We have recently confirmed that GN4 cells
exhibit approximately 5 times more Ang II-dependent activa-
tion and 2–3-fold more CADTK protein than WB cells (5).
Treatment with Ang II or the ionophore A23187 resulted in a
significantly larger activation of p70S6K in GN4 cells compared
with WB cells (Fig. 8A). Typically, the ability of Ang II or
A23187 to activate p70S6K was at least 2–3-fold higher in GN4
cells than in WB cells and was independent of the length of
2 L. Xiong, unpublished observations. 3 L. Xiong, unpublished data.
FIG. 6. TPA activates p90RSK but not p70S6K in GN4 cells. Se-
rum-starved GN4 cells were stimulated with Ang II (AgII, 1 mM) or TPA
(100 nM) for the amount of time indicated. In some experiments, cells
were incubated with 1 mM TPA 24 h prior to collection. Cell lysates were
prepared as described earlier and assayed for p70S6K (A) or p90RSK (B)
activity. Kinase activity is plotted as pmol/min/ml, and the results
represent the mean 6 S.E. (bars) of duplicate samples. Data plotted are
representative of n 5 4 experiments. Cont, control.
FIG. 7. Genistein inhibits the activation of CADTK and p70S6K
by Ang II. A, p70S6K activity, serum-starved GN4 cells were incubated
with Me2SO (carrier for genistein) or genistein (Gen) for 15 min prior to
the addition of Ang II (1 mM). After incubating cells with Ang II for 20
min, the cells were harvested, and the cell lysates were assayed for S6
kinase activity. The activity is plotted as radioactivity (cpm, 32P) incor-
porated into the ribosomal S6 protein and represents the mean 6 S.E.
(bars) of duplicate samples. Data plotted are representative of n 5 3
experiments. Cont, control. B, CADTK, GN4 cells grown in 6-cm plates
were serum-starved and incubated with the concentrations of genistein
indicated for 15 min. After incubation with genistein, the cells were
treated with 1 mM Ang II for 90 s, and the cells were washed twice with
PBS and harvested in RIPA buffer (1 ml). The amount of tyrosine
autophosphorylation on CADTK was determined by immunoprecipita-
tion with CADTK-specific antisera followed by PT66 antiphosphoty-
rosine immunoblotting as described under “Experimental Procedures.”
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exposure to these compounds. Similarly, thapsigargin stimu-
lated a similar 2–3-fold higher increase in S6 kinase activity in
GN4 cells (data not shown).
To eliminate the possibility that the enhanced calcium-de-
pendent activation was simply due to increased expression of
the p70S6K in GN4 cells, the amount of p70S6K activity and
protein was compared in the two cell lines by immunoblotting
and activity assays as described earlier. As determined by
immunoblotting, the amount of the p70S6K protein and the
nuclear form of this kinase (p85S6K) (33) was comparable in the
two cell types (Fig. 8B). Importantly, in GN4 cells, Ang II,
thapsigargin, and A23187 stimulated a pronounced mobility
shift of both the p70 and p85 S6 kinases; by contrast, much less
mobility shift was observed in WB cells, in agreement with the
S6 kinase activity assays. Furthermore, the protein synthesis
inhibitor anisomycin (20) strongly stimulated the mobility shift
(Fig. 8B) and activity of p70S6K (and p85S6K) equivalently in
WB and GN4 cells (Fig. 8C). These results demonstrate that
differences in p70S6K or p85S6K expression do not account for
the enhanced activation by calcium in GN4 cells. Instead these
results suggest that the increased expression of CADTK in
GN4 cells facilitates the activation of p70S6K by Ang II or
calcium stimuli.
DISCUSSION
Ang II has numerous effects on rat liver epithelial cells. It is
a weak mitogen, a response that is initiated via the AT1 recep-
tor, transduced by Gq protein stimulation of phospholipase C,
and effected by serine, threonine, and tyrosine phosphorylation
(1). Elevating intracellular calcium with thapsigargin or iono-
phore (A23187) mimics the Ang II-stimulated increase in pro-
tein tyrosine phosphorylation in GN4 cells (2), and our labora-
tory has recently isolated a likely candidate for the calcium-
stimulated entity that regulates tyrosine phosphorylation, a
novel CADTK. Incubating GN4 cells with Ang II or agonists
that raise intracellular calcium (i.e. thapsigargin and A23187)
activates CADTK (4), whereas incubation with the calcium
chelator BAPTA-AM inhibits activation of this enzyme. The
effect of calcium on CADTK is indirect; adding calcium or
calcium and calmodulin to cell lysates does not activate
CADTK, and thus the mechanism by which calcium and other
signals regulate this enzyme remains to be established.
In addition to activating PKC, the calcium- and calmodulin-
dependent protein kinase, and CADTK in GN4 cells, Ang II
also activates MAPK and JNK and increases AP-1 binding (the
latter can be accomplished in a PKC-independent manner) (10).
We now demonstrate Ang II and calcium-dependent activation
of p70S6K. The challenge is to discern which of these multiple
Ang II-dependent pathways are downstream of PKC, calcium
and calmodulin, CADTK, or even G-protein bg subunits.
We began this process by purifying CADTK; peptide and
cDNA cloning has identified this enzyme as the rat homologue
of a novel human nonreceptor tyrosine kinase, PYK-2 (4–6).
Using PC12 cells, PYK-2 was shown to be activated by elevat-
ing intracellular calcium or PKC activity. In these cells, PYK-2
stimulation increased MAPK activity, providing a potential
mechanism for calcium-dependent regulation of MAPK in these
and other cells (6, 52). In contrast, our studies in rat epithelial
cells demonstrate that a calcium signal (i.e. thapsigargin and
A23187) does not significantly activate MAPK and that Ang
II-dependent MAPK activation is primarily a PKC-dependent
process.2 Instead, Ang II and a calcium signal (thapsigargin)
substantially activate JNK in a calcium-dependent manner
(10). In fact, the Ang II effect is PKC-independent and is
amplified in cells depleted of PKC. JNK activation by Ang II
and thapsigargin correlates with increased expression and ty-
rosine autophosphorylation of CADTK in our rat liver epithe-
lial cells. We have shown that the chemically transformed GN4
cell line expresses more CADTK than the parental cell line
(WB), and the activation of CADTK by Ang II is approximately
5-fold greater in confluent GN4 cells when compared with WB
cells. Activation of JNK by Ang II and thapsigargin is also
5-fold higher in GN4 cells, whereas the total JNK activity
induced by stress (e.g. anisomycin) is equal in WB and GN4
cells. Thus in GN4 cells, CADTK is not involved in MAPK
activation but is likely to be a mediator of signaling to JNK.
FIG. 8. Increased expression of CADTK in GN4 cells correlates
with increased activation of p70S6K by calcium stimuli. A, serum-
starved GN4 cells were incubated with 1 mM A23187 (å) or 1 mM Ang II
(l), and serum-starved WB cells were treated with 1 mM A23187 (Ç) or
1 mM Ang II (E) for the lengths of time indicated. The cells were washed
twice with PBS, and the cell lysates were assayed for p70S6K activity.
The activity is plotted as radioactivity (cpm, 32P) incorporated into the
ribosomal S6 protein and represents the mean 6 S.E. (bars) of duplicate
samples. Data plotted are representative of n 5 3 experiments. B, GN4
and WB cells were stimulated with Ang II (1 mM), thapsigargin (Thaps,
2 mM), A23187 (1 mM), or anisomycin (Anis., 10 mg/ml) for 20 min. Cell
lysates were prepared, and the p70S6K was detected by immunoprecipi-
tation and immunoblotting as described earlier. C, GN4 (solid bars) and
WB (hatched bars) cells were serum-starved and incubated with aniso-
mycin (Anis, 10 mg/ml) for 20 min, after which the cells were harvested
and assayed for p70S6K activity as described earlier. The activity is
plotted as radioactivity (cpm, 32P) incorporated into the ribosomal S6
protein and represents the mean 6 S.E. (bars) of duplicate samples.
Data plotted are representative of n 5 2 experiments. cont, control.
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Because some of the stimuli known to activate JNK also
increase p70S6K activity in other cell types, (i.e. Ang II (11) and
anisomycin (20)), we compared the ability of a calcium signal to
regulate p70S6K in epithelial cells. In this study we find that
like JNK (10), p70S6K is regulated by agonists that raise intra-
cellular calcium, whereas neither p90RSK nor MAPK is affected
by the calcium-activated pathway. This is contrasted to results
in PC12 cells (6, 52) and suggests that the ability of calcium to
regulate these signaling pathways is cell type-specific.
The role of intracellular calcium and Ang II (through its
effects on intracellular calcium) in stimulating p70S6K has not
been studied extensively. In one article, A23187 weakly acti-
vated p70S6K in Swiss 3T3 fibroblasts (53), a cell line that does
not appear to contain CADTK.2 Earlier, the work of Meier et al.
(54) reported the activation of an S6 kinase in kidney epithelial
cells in response to calcium stimuli (A23187), although the
identity of this kinase was not established. It is clear that in
this study we were measuring the calcium-dependent activa-
tion of p70S6K in cell lysates. First, although the cell lysate
assay could detect p90RSK phosphorylation of the 40 S ribo-
somes, we have used a specific immune complex assay to show
that there is little if any thapsigargin-dependent p90RSK acti-
vation. Second, all our assay data have been confirmed by
immunoblot analysis of the p70S6K mobility shift, an assay that
highly correlates with the activation. Third, rapamycin, which
inhibits p70S6K but not p90RSK activation, abolished the Ang II-
or thapsigargin-dependent activation of 40 S ribosome phos-
phorylation in cell lysates.
Importantly, our results suggest that most of the Ang II-de-
pendent activation of p70S6K is calcium-dependent. Preincuba-
tion with BAPTA prevented the Ang II-dependent activation of
p70S6K but not p90RSK. Instead, p90RSK and MAPK were sub-
stantially activated by BAPTA, alone or in the presence of Ang
II. At this point, the mechanism of the BAPTA effect is unclear;
we can only speculate that calcium may regulate one or more
phosphatases in the MAPK cascade or that BAPTA has a
non-calcium-dependent effect on the MAPK pathway. We also
cannot exclude that additional G-protein-coupled signals, e.g.
bg subunit or other G-protein-dependent responses, contribute
to the stimulation of p70S6K by Ang II. Recently the activation
of p70S6K by receptors coupled to Gi has been described, sup-
porting a potential role for bg subunits in the regulation of
p70S6K (55).
In this study we also found that agonists that increase in-
tracellular calcium (A23187, thapsigargin, and Ang II) in GN4
cells activate p70S6K following a rapid stimulation of CADTK.
The cell-permeable chelator BAPTA-AM inhibited the activa-
tion of both CADTK and p70S6K by thapsigargin, A23187, or
Ang II, consistent with a role for CADTK upstream of p70S6K in
these cells. In further support of a role for CADTK, the calcium-
and Ang II-dependent activation of p70S6K was prevented by
genistein at concentrations similar to those required to inhibit
the thapsigargin-dependent JNK activation and the thapsigar-
gin- and Ang II-dependent tyrosine phosphorylation of CADTK
substrates (e.g. paxillin) in vivo.2 Other findings linking
CADTK to the p70S6K pathway come from a comparison of
p70S6K activity in WB and GN4 cells. The GN4 cell line ex-
presses 2–3-fold greater CADTK and has 5-fold greater Ang-
II-dependent CADTK and JNK activation (5). GN4 cells also
exhibit 2–3-fold greater p70S6K activation in response to Ang II
and thapsigargin. The failure of p70S6K to match the 5-fold
difference in CADTK and JNK activation between GN4 and
WB cells may well stem from the complex pathway to p70S6K,
which appears to involve regulation of at least two upstream
kinase pathways (see below).
One possibility is that a calcium signal may be activating
PI-3 kinase, since low concentrations of wortmannin (50 nM)
inhibited the activation of p70S6K by A23187, thapsigargin, or
Ang II. Numerous studies have suggested that PI-3 kinase is
an upstream mediator of p70S6K activity (reviewed in Ref. 12),
although much of the evidence for PI-3 kinase (including our
study) has been obtained with the inhibitor wortmannin (48),
the selectivity of which has been recently questioned (56). With
the caveat of specificity, the activation of CADTK by Ang II or
thapsigargin is not inhibited by wortmannin,2 suggesting that
PI-3 kinase is downstream or unrelated to the calcium-depend-
ent activation of CADTK. Wortmannin also does not inhibit
JNK activation, another pathway linked to the regulation of
CADTK in GN4 cells.2 Thus, if CADTK is a common activator
of both p70S6K and JNK in GN4 cells, as our results suggest, at
some point the signaling pathways diverge such that a wort-
mannin-sensitive step is specific to the p70S6K pathway.
Our results are also consistent with the calcium-dependent
activation of another limb of the p70S6K pathway, the one that
activates the rapamycin-sensitive kinase, i.e. FRAP/RAFT. Ra-
pamycin inhibits the activity of the FRAP/RAFT kinases by
binding to its cognate binding protein, FKB12, thus inhibiting
p70S6K stimulation (16). However, like the PI-3 kinases, the
role of FRAP/RAFT in regulating p70S6K is poorly understood,
largely because substrates for these kinases remain to be iden-
tified. Again the calcium-dependent pathway to JNK and
p70S6K is divergent in GN4 cells, since rapamycin blocks Ang
II- and thapsigargin-dependent p70S6K activation but does not
effect the stimulation of CADTK or JNK by these agonists.2
In addition to increasing intracellular calcium, Ang II also
stimulates PKC activity (1, 5). Despite the fact that PKC has
been shown to activate p70S6K in other cell types (57), our
results do not support a role for PKC in the regulation of p70S6K
in GN4 cells. Although Ang II stimulated p70S6K in a manner
similar to thapsigargin or A23187, TPA alone did not increase
p70S6K activity in GN4 cells, although MAPK and p90RSK were
activated as expected.
TPA also increases CADTK activity in these cells, albeit less
potently than Ang II and more slowly than thapsigargin. These
results present a paradox, since our studies suggest that
CADTK is upstream of p70S6K, and yet TPA does not activate
p70S6K. We have found that a brief (5 min) TPA pretreatment
inhibited the activation of p70S6K by Ang II or thapsigargin by
approximately 40% in GN4 cells.4 Similarly, an even more
profound inhibitory effect of PKC has been found on the acti-
vation of JNK by calcium stimuli or Ang II in GN4 cells.2 Taken
together, these studies demonstrate that PKC alone is incapa-
bleofactivatingp70S6Kandmayinhibitthedownstreamcalcium-
dependent signals to both JNK and p70S6K in GN4 cells.
In summary, we have demonstrated a calcium-dependent
pathway that results in substantial activation of p70S6K. This
calcium-dependent pathway has characteristics similar to to
the calcium-dependent pathway to JNK that we have previ-
ously studied in this cell line (5, 10). Intriguingly, this calcium-
dependent pathway does not activate MAPK or p90RSK; instead
these enzymes are activated in PKC-dependent manner. Con-
siderable circumstantial evidence points to CADTK as an ini-
tial mediator of the calcium signal to both JNK and p70S6K.
However, the pathway to these enzymes clearly diverges at
some point such that the calcium-dependent activation of JNK
is insensitive to wortmannin and rapamycin, whereas the ac-
tivation of p70S6K is completely inhibited by these compounds.
The exact signaling downstream from CADTK and, in fact,
unequivocal proof of CADTK involvement must await further
studies.
4 L. M. Graves, unpublished observations.
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